Open AccessPediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant
Author(s) -
Anna Di Sessa,
Giuseppina Rosaria Umano,
Grazia Cirillo,
Antonio Paride Passaro,
Valentina La Verde,
Domenico Cozzolino,
Stefano Guarino,
Pierluigi Marzuillo,
Emanuele Miraglia del Giudice
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i36.5474
Subject(s) - fatty liver , medicine , renal function , steatosis , gastroenterology , allele , kidney disease , liver function , population , metabolic syndrome , endocrinology , obesity , disease , biology , gene , genetics , environmental health
Growing evidence supports a genetic link between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). Interesting data demonstrated that both the major NAFLD risk polymorphisms such as the I148M polymorphism in the patatin like phospholipase containing domain 3 ( PNPLA3 ) and the E167K allele in the transmembrane 6 superfamily member 2 gene ( TM6SF2 ) affect renal function. Recently the hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ) gene has been recognized as a novel genetic variant involved in NAFLD pathophysiology. In particular, it has been showed the protective effect of the rs72613567:TA variant of this gene against liver damage both in adults and children.